Leerink Partnrs Has Pessimistic Outlook of MAZE Q1 Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Investment analysts at Leerink Partnrs cut their Q1 2025 earnings estimates for shares of Maze Therapeutics in a report issued on Monday, March 31st. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.64) for the quarter, down from their prior forecast of ($0.58). Leerink Partnrs has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Maze Therapeutics’ Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.66) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.33) EPS, FY2026 earnings at ($2.78) EPS and FY2027 earnings at ($2.55) EPS.

Several other brokerages have also weighed in on MAZE. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 25th. JPMorgan Chase & Co. assumed coverage on Maze Therapeutics in a report on Tuesday, February 25th. They set an “overweight” rating and a $30.00 price target for the company. Guggenheim restated a “buy” rating and issued a $19.00 price objective on shares of Maze Therapeutics in a report on Wednesday. Finally, Leerink Partners assumed coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They set an “outperform” rating and a $28.00 target price for the company. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Maze Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $25.67.

Maze Therapeutics Stock Performance

NASDAQ:MAZE opened at $9.32 on Thursday. Maze Therapeutics has a 1-year low of $9.30 and a 1-year high of $17.00.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Monday, March 31st. The company reported ($18.32) earnings per share for the quarter, missing the consensus estimate of ($7.60) by ($10.72).

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.